These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 16118627)

  • 1. Immunocytochemical detection of XIAP in body cavity effusions and washes.
    Wu M; Yuan S; Szporn AH; Gan L; Shtilbans V; Burstein DE
    Mod Pathol; 2005 Dec; 18(12):1618-22. PubMed ID: 16118627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology?
    Lyons-Boudreaux V; Mody DR; Zhai J; Coffey D
    Arch Pathol Lab Med; 2008 Jan; 132(1):23-8. PubMed ID: 18181669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical detection of XIAP in mesothelium and mesothelial lesions.
    Wu M; Sun Y; Li G; Desman G; Wang B; Gil J; Burstein DE
    Am J Clin Pathol; 2007 Nov; 128(5):783-7. PubMed ID: 17951200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical detection of the X-linked inhibitor of apoptosis protein (XIAP) in cervical squamous intraepithelial neoplasia and squamous carcinoma.
    Burstein DE; Idrees MT; Li G; Wu M; Kalir T
    Ann Diagn Pathol; 2008 Apr; 12(2):85-9. PubMed ID: 18325467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
    Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
    Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma.
    Kleinberg L; Lie AK; Flørenes VA; Nesland JM; Davidson B
    Hum Pathol; 2007 Jul; 38(7):986-994. PubMed ID: 17350081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical detection of X-linked inhibitor of apoptosis in head and neck squamous cell carcinoma.
    Nagi C; Xiao GQ; Li G; Genden E; Burstein DE
    Ann Diagn Pathol; 2007 Dec; 11(6):402-6. PubMed ID: 18022123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
    Shield PW; Papadimos DJ; Walsh MD
    Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-erbB-2 oncoprotein immunostaining in serous effusions.
    Ascoli V; Scalzo CC; Nardi F
    Cytopathology; 1993; 4(4):207-18. PubMed ID: 8104524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GLUT1 glucose transporter: a highly sensitive marker of malignancy in body cavity effusions.
    Burstein DE; Reder I; Weiser K; Tong T; Pritsker A; Haber RS
    Mod Pathol; 1998 Apr; 11(4):392-6. PubMed ID: 9578091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic value of p53 and ki67 immunostaining for distinguishing benign from malignant serous effusions.
    Hafez NH; Tahoun NS
    J Egypt Natl Canc Inst; 2011 Dec; 23(4):155-62. PubMed ID: 22776843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility of immunocytochemical detection of tumor markers (XIAP, phosphohistone H1 and p63) in FNA cellblock samples from head and neck squamous cell carcinoma.
    Wu M; Kafanas A; Gan L; Kohtz DS; Zhang L; Genden E; Burstein DE
    Diagn Cytopathol; 2008 Nov; 36(11):797-800. PubMed ID: 18831009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of pleural fluid survivin and XIAP for the diagnosis of malignant pleural effusion.
    Li J; Li ZN; Bao QL; Ge LP; Li XQ; Chen P
    Tumour Biol; 2012 Oct; 33(5):1803-10. PubMed ID: 22696161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
    Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
    Hum Pathol; 2010 May; 41(5):745-50. PubMed ID: 20060157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers.
    Davidson B; Risberg B; Kristensen G; Kvalheim G; Emilsen E; Bjåmer A; Berner A
    Virchows Arch; 1999 Jul; 435(1):43-9. PubMed ID: 10431845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic utility of GLUT-1 expression in the cytologic evaluation of serous fluids.
    Afify A; Zhou H; Howell L; Paulino AF
    Acta Cytol; 2005; 49(6):621-6. PubMed ID: 16450901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical detection of antiapoptotic protein X-linked inhibitor of apoptosis in mammary carcinoma.
    Jaffer S; Orta L; Sunkara S; Sabo E; Burstein DE
    Hum Pathol; 2007 Jun; 38(6):864-70. PubMed ID: 17350670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations.
    Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
    Diagn Cytopathol; 2011 Jun; 39(6):395-401. PubMed ID: 21574259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
    Bassarova AV; Nesland JM; Davidson B
    Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy.
    Gieseler F; Lühr I; Kunze T; Mundhenke C; Maass N; Erhart T; Denker M; Beckmann D; Tiemann M; Schulte C; Dohrmann P; Cavaillé F; Godeau F; Gespach C
    Thromb Haemost; 2007 Jun; 97(6):1023-30. PubMed ID: 17549306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.